BRUSSELS, 1 July 2026: SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from […]

19 May 2026: SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire the exclusive development and commercialisation rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) […]

SERB Pharmaceuticals, a global specialty pharmaceutical company focused on rare diseases and medical emergencies, announced that ThyroSafe potassium iodide tablets are now commercially available in a 130 mg dose.